Side-by-side comparisons of the compounds researchers most often weigh against each other — mechanism, trial data, and regulatory status, reported rather than recommended.
Compound Comparisons
- Retatrutide vs Tirzepatide — triple agonist against dual, and what the third receptor actually changes.
- Semaglutide vs Tirzepatide — single against dual, with the one head-to-head trial in the category.
- BPC-157 vs TB-500 — vascular supply against cell migration, and the TB-500 naming problem.
Background Reading
Comparisons assume you already know what class of compound you’re looking at. If you don’t, start with the background guides:
- GLP-1 receptor agonists — the class behind semaglutide, tirzepatide and retatrutide, and what the published trials measured.
- Growth hormone secretagogues — compounds that prompt the pituitary rather than supplying growth hormone directly.
- Approved medicines vs research compounds — which of these are real medicines, and which are not.
Every compound referenced is supplied by CompoundPlug for laboratory research only. See Research Use Only.